Plasma Derived Therapies Market Global Performance Analysis 2026 To 2035

(MENAFN- Market Press Release) September 30, 2026 12:44 am - Plasma Derived Therapies Market Size is valued at USD 22.36 Bn in 2025 and is predicted to reach USD 46.62 Bn by the year 2035 at 8.2% CAGR during the forecast period for 2026 to 2035.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Plasma Derived Therapies Market Size, Share & Trends Analysis Report By Product Type (Immunoglobulin, Coagulation Factors, Albumin), Application Type (Haemophilia, Primary Immunodeficiency Disease, Idiopathic Thrombocytopenic Purpura), Region, Market Outlook And Industry Analysis 2035"

Plasma Derived Therapies Market Size is valued at USD 22.36 Bn in 2025 and is predicted to reach USD 46.62 Bn by the year 2035 at 8.2% CAGR during the forecast period for 2026 to 2035.

Get Free Access to Demo Report, Excel Pivot and ToC:

Plasma-derived therapeutics are essential in the treatment and management of a broad range of serious and chronic medical conditions, including immune deficiencies, bleeding disorders, and certain rare diseases. These products are manufactured from human plasma through fractionation and purification processes that separate therapeutically valuable proteins and antibodies. Key plasma-derived products include immunoglobulins, albumin, and coagulation factors, many of which are used in the management of conditions requiring long-term or specialized treatment.

The global plasma-derived therapeutics market is expected to expand as the prevalence of chronic and immune-related disorders increases and demand for plasma-derived medicines continues to rise. Advancements in plasma collection, fractionation, purification, and viral safety technologies are improving manufacturing capabilities and supporting the development of high-quality plasma-derived products. The clinical importance of these therapies, combined with their use in conditions for which therapeutic alternatives may be limited, continues to reinforce their role within modern healthcare systems.

List of Prominent Players in the Plasma Derived Therapies Market:
.CSL Behring
.Takeda Pharmaceutical Company Limited
.Biotest AG
.Octapharma
.BPL
.ADMA Biologics
.Grifols
.Kedrion
.Kamada Pharmaceuticals
.SK Plasma
.Pfizer

Add our site to Google Preferred Sources for quality content:

Market Dynamics

Drivers

The plasma-derived therapeutics market is experiencing sustained growth, supported by the increasing prevalence of chronic, immune-related, bleeding, and rare diseases that require specialized plasma-based treatments. Governments and healthcare organizations are strengthening healthcare infrastructure and improving access to essential therapies, creating a more favorable environment for the adoption of plasma-derived products. Insurance coverage and reimbursement mechanisms can further improve treatment affordability and support patient access, particularly for therapies requiring long-term or recurring administration.

Increasing investment in research and development is also supporting market expansion. Leading pharmaceutical and plasma-product manufacturers are broadening their portfolios through product development, manufacturing capacity expansion, and technological improvements in plasma collection and fractionation. These efforts are contributing to greater availability of plasma-derived therapies and supporting their penetration across international markets.

Challenges

Despite favorable long-term prospects, the market faces challenges related to plasma collection, supply availability, manufacturing complexity, and healthcare disruptions. The COVID-19 pandemic highlighted the importance of resilient plasma collection and supply systems while also demonstrating the potential role of plasma-based interventions during public health emergencies. In August 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization for COVID-19 convalescent plasma for the treatment of hospitalized patients, based on the scientific evidence available at that time. The authorization was subsequently revised and was ultimately revoked in August 2025, reflecting the evolving evidence and regulatory status of the therapy.

Beyond pandemic-related disruptions, the industry remains exposed to fluctuations in plasma collection, donor availability, transportation, and manufacturing capacity. The highly specialized nature of plasma fractionation and the need for stringent quality and safety controls can also increase production costs and operational complexity. These factors may constrain supply expansion and affect the accessibility of plasma-derived products in certain markets.

Regional Trends

North America is expected to maintain a significant position in the global plasma-derived therapeutics market, supported by established healthcare infrastructure, a substantial patient population requiring plasma-based therapies, advanced biotechnology capabilities, and strong investment in research and development. The region also benefits from sophisticated plasma collection and fractionation networks, established reimbursement mechanisms, and a regulatory environment that supports the development and commercialization of biologic therapies.

The presence of major industry participants and specialized plasma-product manufacturers further strengthens the regional ecosystem. Continued investment in manufacturing capacity, therapeutic innovation, plasma collection infrastructure, and strategic industry collaborations is expected to support market development. In addition, increasing healthcare expenditure and continued demand for immunoglobulins, albumin, and coagulation factors are expected to reinforce the importance of North America within the global plasma-derived therapeutics market.

Recent Developments:
.In January 2022, The European Union (EU) announced an expansion of the indication for the subcutaneously administered human immunoglobulin cutaquig, according to Octapharma AG. Patients with acquired immune weaknesses would have more diverse treatment options thanks to the extension.
.In January 2022, The existing shareholders of Kedrion S.p.A., the Marucci family and FSI, and Permira formed a partnership to acquire and combine Kedrion with Bio Products Laboratory (BPL). The collaboration of the two businesses would become a dominant global force for drugs made from human plasma that are used to treat serious and uncommon illnesses.
Unlock Your GTM Strategy:
Segmentation of Plasma Derived Therapies Market-
By Product Type-
.Immunoglobulin
.Coagulation factors
.Albumin
.Others
By Application Type-
.Haemophilia
.Primary Immunodeficiency Disease
.Idiopathic Thrombocytopenic Purpura
.Others
By Region-
North America-
.The US
.Canada
.Mexico
Europe-
.Germany
.The UK
.France
.Italy
.Spain
.Rest of Europe
Asia-Pacific-
.China
.Japan
.India
.South Korea
.South East Asia
.Rest of Asia Pacific
Latin America-
.Brazil
.Argentina
.Rest of Latin America
Middle East & Africa-
.GCC Countries
.South Africa
.Rest of Middle East and Africa

Read Overview Report-

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit:
Tel: +1 607 400-7072
Asia: +91 79 72967118
...

MENAFN01102026003520003262ID1111744356